生命科学资讯

Lonza sells capsule and health ingredients unit for $2.2B

Lonza sells capsule and health ingredients unit to UK's Lone Star for $2.2B - Endpoints News

Servier to buy Day One for $2.5B, gaining rare oncology medicines

Solid Biosciences gets $240M for pipeline; Roche expounds on lupus data

Post-Hoc Live: What will the US government do about China biotech?

Pfizer gets obesity drug approval in China shortly after buying local rights

Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president

FDA official questions need for advisory committees

Kura says its menin inhibitor is preferred treatment for some payers

Roche partner Zealand posts Phase 2 data for amylin obesity drug

Roche, Element and Ultima push toward the $100 genome

FDA approves J&J's multiple myeloma combo as second-line treatment

Helus Pharma's stock slides after psychedelic drug data face questions over dosing

New FDA bonus pilot to address 'workforce challenges'

Eli Lilly's new program aims to boost employer coverage of GLP-1s

Tenaya wins support from Alnylam in cardio disease pact

Health AI dispatch from SF

China is taking on the world’s 10 most expensive medicines

Merck KGaA drops two cancer trials on assets from SpringWorks deal

Novo Nordisk details Irish expansion; EuroAPI’s challenges continue